Molecular predictive and prognostic markers in non-small-cell lung cancer

The Lancet Oncology

Volumn 10, Issue 10, 2009, Pages 1001-1010

  Coate, Linda E ^a   John, Thomas ^a   Tsao, Ming Sound ^a   Shepherd, Frances A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BRCA1 PROTEIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; IFOSFAMIDE; K RAS PROTEIN; NAVELBINE; PACLITAXEL; PLACEBO; PROTEIN P27; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE MESSENGER 1; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DISEASE FREE SURVIVAL; EXCISION REPAIR; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MARKER GENE; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL TIME;

CARCINOMA, NON-SMALL-CELL LUNG; GENETIC MARKERS; HUMANS; LUNG NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349376330     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70155-X     Document Type: Review

References (57)

1. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., and Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
2. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
3. Strauss G.M., Herndon II J.E., Maddaus M.A., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26 (2008) 5043-5051
4. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
5. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
6. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24 (1998) 331-344
7. Altaha R., Liang X., Yu J.J., and Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14 (2004) 959-970
8. Simon G.R., Sharma S., Cantor A., Smith P., and Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127 (2005) 978-983
9. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
10. Rosell R., Skrzypski M., Jassem E., et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2 (2007) e1129
11. Lord R.V., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
12. Tsao M.S., Aviel-Ronen S., Ding K., et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 25 (2007) 5240-5247
13. Shepherd F.A., Pereira J.R., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
14. Zhu C.Q., da Cunha Santos G., Ding K., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26 (2008) 4268-4275
15. Lynch T.J., Patel T., Dreisbach L., et al. Overall survival (OS) results from the phase III trial BMS 099: cetuximab taxane/carboplatin as 1st-line treatment for advanced NSCLC. J Thorac Oncol 11 (2008) S305
16. Khambata-Ford S., Harbison C.T., Hart L.L., et al. K-Ras mutations (MT) and EGFR-related markers as potential predictors of cetuximab benefit in 1st line advanced NSCLC: results from the BMS099 study. J Thorac Oncol 3 suppl (2008) S304
17. Filipits M., Pirker R., Dunant A., et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 25 (2007) 2735-2740
18. Seve P., Lai R., Ding K., et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13 (2007) 994-999
19. Le Chevalier T., Scagliotti G., Natale R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80
20. Zheng Z., Chen T., Li X., Haura E., Sharma A., and Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356 (2007) 800-808
21. Rosell R., Danenberg K.D., Alberola V., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10 (2004) 1318-1325
22. Simon G., Sharma A., Li X., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 25 (2007) 2741-2746
23. Quinn J.E., James C.R., Stewart G.E., et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13 (2007) 7413-7420
24. Cobo Sr. M., Massuti B., Morán T., et al. Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels. Proc Am Soc Clin Oncol 26 20 suppl (2008) abstr 7533.
25. Burke L., Flieder D.B., Guinee D.G., et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 11 (2005) 232-241
26. Steels E., Paesmans M., Berghmans T., et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18 (2001) 705-719
27. Huncharek M., Muscat J., and Geschwind J.F. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 20 (1999) 1507-1510
28. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
29. Eberhard D.A., Johnson B.E., Amler L.C., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 (2005) 5900-5909
30. Pirker R., Szczesna A., von Pawel J., et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 26 20 suppl (2008) abstr 3.
31. Van Cutsem E., Lang I., D'haens G., et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. Proc Am Soc Clin Oncol 26 20 suppl (2008) abstr 2.
32. St Croix B., Florenes V.A., Rak J.W., et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 2 (1996) 1204-1210
33. Seve P., Mackey J., Isaac S., et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4 (2005) 2001-2007
34. Seve P., Isaac S., Tredan O., et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11 (2005) 5481-5486
35. Rosell R., Scagliotti G., Danenberg K.D., et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22 (2003) 3548-3553
36. Buckley A.F., and Kakar S. Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. Appl Immunohistochem Mol Morphol 15 (2007) 305-309
37. Hirsch F.R., Dziadziuszko R., Thatcher N., et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer 112 (2008) 1114-1121
38. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., and Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3 (1997) 515-522
39. Fontanini G., De Laurentiis M., Vignati S., et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4 (1998) 241-249
40. Hsieh E.T., Shepherd F.A., and Tsao M.S. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma. Lung Cancer 29 (2000) 151-157
41. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 (2003) 3798-3807
42. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
43. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5034-5042
44. Kim E.S., Hirsh V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372 (2008) 1809-1818
45. Douillard J., Hirsh V., Mok T., et al. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). Proc Am Soc Clin Oncol 26 20 suppl (2008) abstr 8001.
46. Crino L., Cappuzzo F., Zatloukal P., et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 26 (2008) 4253-4260
47. Mok T., Wu Y.L., Thongprasert S., Yang C.H., Chung D., and Saijo N. Phase III, randomised, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer. European Society for Medical Oncology (2008), Annals of Oncology, Stockholm, Sweden
48. Goss G., Ferry D., Wierzbicki R., et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 27 (2009) 2253-2260
49. Hirsch F.R., Herbst R.S., Olsen C., et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26 (2008) 3351-3357
50. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306-13311
51. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
52. Zhu C.Q., Pintilie M., John T., et al. Understanding prognostic gene expression signatures in lung cancer. Clin Lung Cancer (2009) (in press).
53. Lacroix L., Commo F., and Soria J.C. Gene expression profiling of non-small-cell lung cancer. Expert Rev Mol Diagn 8 (2008) 167-178
54. Shedden K., Taylor J.M., Enkemann S.A., et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14 (2008) 822-827
55. Potti A., Dressman H.K., Bild A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 12 (2006) 1294-1300
56. Tsao M.S., Zhu C., Ding K., et al. A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. Proc Am Soc Clin Oncol 26 15 suppl (2008) abstr 7510.
57. Kong S.L., Salto-Tellez M., Leong A.P., Chan Y.H., and Koay E.S. Discordant quantitative detection of putative biomarkers in nodal micrometastases of colorectal cancer: biological and clinical implications. J Clin Pathol 58 (2005) 839-844